InsidersTradesSigma
Total declarations
Company
▲ Purchases (10 ops.)
▼ Sales (0 ops.)
Insider track record
CFODisclosed buys
10
Disclosed sells
0
T+90 hit rate
10%
T+90 mean return
-22.1%
Across 10 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Sims Andrew John Hugh MacIntyre, Chief Financial Officer. Officer active across 1 company, notably Plus Therapeutics, INC.. Cumulatively, 10 filings have been logged. Breakdown: 10 buys · 0 sell. Total volume traded: €34k. History available since 27 July 2021. The latest transaction was filed on 10 September 2024 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Declarations10 total
▲
4,098 shares@ US$1.2714.0% of flowCommon StockSEC:0000950170-24-105330:0
Canonical exit: 9 Dec 2024 (T+90)
▲
4,902 shares@ US$2.0427.6% of flowCommon StockSEC:0000950170-24-057456:0
Canonical exit: 6 Aug 2024 (T+90)
▲
3,000 shares@ US$0.6720.0053% mcap9.6% of flowCommon StockSEC:0001209191-22-025719:0
Canonical exit: 25 Jul 2022 (T+90)
▲
2,000 shares@ US$1.09990.0054% mcap9.9% of flowCommon StockSEC:0001209191-22-015201:0
Canonical exit: 30 May 2022 (T+90)
▲
1,000 shares@ US$1.86430.0045% mcap8.2% of flowCommon StockSEC:0001209191-21-062868:0
Canonical exit: 31 Jan 2022 (T+90)
▲
1,000 shares@ US$1.86434.8% of flowCommon StockSEC:0001209191-21-062868
Canonical exit: 31 Jan 2022 (T+90)
▲
2,000 shares@ US$1.66940.0080% mcap14.6% of flowCommon StockSEC:0001209191-21-061723:0
Canonical exit: 24 Jan 2022 (T+90)
▲
2,000 shares@ US$1.66948.5% of flowCommon StockSEC:0001209191-21-061723
Canonical exit: 24 Jan 2022 (T+90)
▲
1,986 shares@ US$2.050.0096% mcap17.5% of flowCommon StockSEC:0001209191-21-048660:0
Canonical exit: 25 Oct 2021 (T+90)
▲
1,986 shares@ US$2.0510.2% of flowCommon StockSEC:0001209191-21-048660
Canonical exit: 25 Oct 2021 (T+90)
10 of 10 declarations
About Sims Andrew John Hugh MacIntyre
Sims Andrew John Hugh MacIntyre is Chief Financial Officer at PLUS THERAPEUTICS, INC. In this role, he is responsible for financial management and budgeting strategy for the company. His expertise in finance allows him to optimize financial performance and ensure regulatory compliance. Andrew plays a key role in strategic planning and financial results analysis.
